Articles published in Current Opinion in Drug Discovery & Development , Current Opinion in Molecular Therapeutics , Current Opinion in Investigational Drugs and IDrugs are by invitation based on the recommendations from our renowned Editorial Board. We also welcome proposals; authors wishing to submit an article for publication should contact the relevant Journal Editor with an outline/abstract, which will be reviewed by a member of the Editorial Board for approval. Our journals are review-based (we do not publish primary papers) and all articles are peer reviewed. IDrugs contains feature articles that highlight and debate topics of current interest in the pharmaceutical field.

PREPARATION OF MANUSCRIPTS

The Current Opinion journals use the leading online manuscript submission system – Manuscript Central – for the invitation, submission and peer review process. The site address is http://mc.manuscriptcentral.com/keyopinions . Manuscript Central allows for easy administrative, editing and reviewing capabilities, reducing time to publication. Our author guidelines are located under ‘Instructions and Forms’ and are provided by our Editors once a commission and deadline for submission have been agreed.

The Current Opinion journals bibliographic styles are also available in EndNote to make the citing of references in papers and reviews as effortless as possible.

POINTS TO CONSIDER

• Is the subject of sufficient interest to other people?
• Am I writing too much with specialists in mind?
• Has the subject been sufficiently covered in other recent publications?

REPRINTS

Reprints or PDFs can be purchased by contacting ts.ids@thomson.com

EDITORIAL CORRESPONDENCE

Address all correspondence to:
Commissioned Key Opinions
Thomson Reuters
77 Hatton Garden
London
EC1N 8JS
UK

TS-EMEA-Commissioning@thomson.com